Up to 45,000 people living with Chagas disease in the US at risk of severe COVID-19 complications

Washington DC/Los Angeles/New York – 14 April 2020
First “World Chagas Day” highlights how vulnerable many patients are
Doctors in the United States that treat people with Chagas disease, a parasitic illness transmitted by the “kissing bug” in the Americas, are increasingly worried about the estimated 30,000 to 45,000 people that are at increased risk of complications from COVID-19 because they have Chagas-related heart problems.

Marking World Chagas Day for the first time to help give visibility to this neglected disease

From a world under lockdown due to the coronavirus pandemic – 13 April 2020
Starting this year, April 14th will serve to give visibility in the global health agenda to the challenges faced by people affected by Chagas disease, most of whom live in low-income contexts and highly vulnerable health conditions.
For the first time in the 111 years since the first case of Chagas disease was diagnosed in humans, we are celebrating World Chagas Day, which was established by the World Health Organization (WHO) on April 14th to remind us of the challenges faced by those affected by this neglected disease.

Coalition launched to accelerate research on the prevention and treatment of COVID-19 in low- and middle-income countries

2 April 2020

A group of scientists, physicians, funders, and policy makers from over 70 institutions from over 30 countries have launched an international coalition to respond to COVID-19 in resource-poor settings. The COVID-19 Clinical Research Coalition aims to accelerate desperately needed COVID-19 research in those areas where the virus could wreak havoc on already-fragile health systems and cause the greatest health impact on vulnerable populations.

Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

Basel, Switzerland – 25 February 2020

  • LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
  • Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
  • DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
  • Leishmaniasis, which is transmitted by the sandfly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year

Novartis and DNDi have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers.

Brazil’s Ministry of Health and CNPq to invest in researching new treatments for leishmaniasis and Chagas disease

Brasilia, Brazil – 5 December 2019
Studies may lead to therapeutic alternatives for people living with these neglected tropical diseases
The Brazilian Ministry of Health (the Department of Science and Technology of the Science, Technology and Strategic Inputs Secretariat – Decit/SCTIE) and CNPq (National Council for Scientific and Technological Development) will invest around R$ 1,5 million (US$ 370,000) in research that may lead to the development of a new treatment option for cutaneous leishmaniasis.

HIV treatment for children to be produced for under one dollar a day

Geneva, Switzerland – 29 November 2019
Unitaid and DNDi celebrate partnership with Cipla on World AIDS Day
The Indian pharmaceutical company Cipla has announced their commitment to price the ground-breaking new product Quadrimune, a “4‑in‑1” treatment for young children with HIV, at below a dollar a day. Quadrimune is currently under review by the US Food and Drug Administration (FDA) for use in children between 3 and 25 kg bodyweight.

Public-private partnership launched to develop new drugs for roundworm infections

Geneva – 28 November 2019
“Pan-nematode” drug development platform is part of Europe’s Horizon 2020 programme
A new consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies has teamed up to develop novel drugs for infections caused by parasitic worms (helminths), a debilitating group of diseases that includes river blindness, lymphatic filariasis, as well as infection with hookworm and whipworm, which together affect close to a billion people.

DNDi receives $29 million to fast-track the development of drugs to help eliminate sleeping sickness and river blindness

Geneva/Seattle – 25  November 2019

DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.

Study shows that African eye worm threatens elimination of river blindness

Washington DC, USA – 20 November 2019
Over four million people will be infected with river blindness in 2025 in areas where African eye worm is present, according to new modelling
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or ‘African eye worm’, according to a study published in Clinical Infectious Diseases.

Not-for-profit research and development can address deadly market failure for neglected patients, paper shows

Berlin, Germany – 30 October 2019
15 years of an ‘experiment in innovation’ to discover and develop affordable new treatments in the public interest
In its first 15 years, DNDi has proven that not-for-profit R&D can deliver effective and affordable new treatments to help fill the drug development pipeline for neglected diseases, an area that was suffering from a deadly lack of attention when the organization was created in 2003, according to a new report released today at the two-day DNDi & Founders’ Symposium in Berlin, Germany.

The French development agency AFD renews its support for the Drugs for Neglected Diseases initiative (DNDi) in researching and developing treatments for neglected tropical diseases

Paris, France – 18 October 2019
Bertrand Walckenaer, Deputy CEO of the Agence Française de Développement (AFD), and Dr Bernard Pécoul, Executive Director of DNDi, signed an agreement today for a project to support the research and development of treatments for neglected tropical diseases. Implementing a strategy to develop suitable, affordable, and safe treatments is a major international challenge; more than one billion people in 149 countries are affected by these diseases. This project is funded by a EUR 8 million grant.

Lack of awareness of Chagas disease in the US leading to unnecessary deaths in vulnerable immigrant communities

New York/Los Angeles – 26 September 2019
New DNDi/CECD/MSF paper published in PLOS Neglected Tropical Diseases on the “silent killer” Chagas disease
Fear, stigma, gaps in the health system, and lack of awareness in the medical community are among the barriers keeping the most vulnerable from accessing essential care for Chagas disease, a leading cause of heart disease in the Americas, according to a paper published today by the not-for-profit drug development organization DNDi, the Center of Excellence for Chagas Disease, and the international medical humanitarian organization MSF.

La cuvée 2018 de la ‘Vigne des Nations’ de la République et canton de Genève dédiée à DNDi en reconnaissance de son travail auprès des patients les plus négligés

Genève, Suisse – 15 Septembre 2019
Après avoir reçu le Prix de l’Innovation 2017 de Genève, DNDi est aujourd’hui honoré par la République et canton de Genève, qui lui dédie la cuvée 2018 de la ‘Vigne des Nations’. Cette récompense salue l’engagement de l’organisation internationale à but non lucratif basée à Genève pour le développement de nouveaux traitements pour les populations les plus négligées atteintes de maladies telles que la maladie du sommeil, le mycétome, la leishmaniose, la maladie de Chagas, les maladies liées aux vers filaires, le VIH/SIDA pédiatrique et l’hépatite C.

Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows

Geneva/New Delhi – 22 July 2019
Results show that a skin condition known as post-kala-azar dermal leishmaniasis (PKDL) could be a threat to elimination of leishmaniasis in South Asia
The results of an innovative “infectivity” study conducted by DNDi and the International Centre for Diarrhoeal Disease Research, Bangladesh confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known as PKDL.

Nationwide hepatitis C screening campaign initiated by the Malaysian Ministry of Health

Kuala Lumpur – 17 July 2019
Supported by Drugs for Neglected Diseases initiative & Foundation for Innovative New Diagnostics, campaign seeks to find the “missing millions” for this silent but curable disease
FIND and DNDi are partnering with the Ministry of Health in Malaysia to launch the country’s biggest-ever screening initiative for the hepatitis C virus.

Following 110 years of neglect, an official day for Chagas disease is declared

Geneva, Switzerland – 24 May 2019
The delegates at the World Health Assembly (WHA) have today approved the creation of a World Chagas Day. People affected by Chagas worldwide celebrate this important step in fighting for recognition of this neglected disease.
The International Federation of People Affected by Chagas Disease (FINDECHAGAS) today celebrates the creation of the World Day of People Affected by Chagas at the 72nd World Health Assembly (WHA) in Geneva, Switzerland.